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Immunohistochemically Detected High Expression of Matrix 
Metalloproteinase-2 as Predictor of Poor Prognosis in Duke’s B Colon 
Cancer
Aim To demonstrate immunohistochemical expression of matrix metal-
loproteinase-2 (MMP-2) protein in Duke’s B colon cancer and deter-
mine its correlation with age, sex, grade, presence of vascular invasion, 
and patients’ overall survival.
Method The study took place from January 1995 to December 1997. We 
determined the expression of MMP-2 in 152 formalin-fixed, paraffin em-
bedded specimens of Duke’s B colon carcinomas by immunohistochemi-
cal analysis using MMP-2 monoclonal antibody. Immunohistochemi-
cal expresssion was scored semiquantitatively. Carcinomas were graded 
as low or high grade. Survival time was analyzed with Kaplan-Meier 
method, and the log-rank test was used to assess the differences between 
groups. Cox proportional hazard regression model was used for multi-
variate survival analysis.
Result Univariate analysis showed that positive staining for MMP-2, 
high histological grade, vascular invasion, male sex, and age >60 years 
were associated with shorter survival in patients with Duke’s B colon 
cancer (P range from 0.023 to <0.001). Multivariate analysis showed that 
only MMP-2 overexpression (P < 0.001; hazard ratio [HR] = 3.64) and 
vascular invasion (P < 0.001; HR = 4.27) were associated with shorter 
overall survival.
Conclusion Expression of MMP-2 is an important independent indica-
tor of shorter survival in patients with Duke’s B colon cancer and should 
be taken into consideration in decision-making on the use of adjuvant 
systemic therapy in patients with Duke’s B colon cancer.
1Department of Internal 
Medicine, Split University 
School of Medicine, Split, 
Croatia
2Department of Pathology, 
Split University School of 
Medicine, Split, Croatia
3Department of Emergency 
Medicine, Split Dalmatian 
County, Split, Croatia 
Željko Šundov1, Snježana Tomić2, Katarina Vilović2, Nenad Kunac2, Marija 
Kalebić3, Joško Bezić2
Snježana Tomić 
Department of Pathology 
Split University Hospital 
Spinčićeva 1 
21000 Split, Croatia 
snjezana.tomic@st.t-com.hr
>  Received: March 25, 2008
>  Accepted: June 23, 2008
>  Croat Med J. 2008;49:636-42




Šundov et al: MMP-2 in Duke’s B Colon Cancers
637
Colorectal carcinoma (CRC) is the third lead-
ing cause of cancer-related mortality in devel-
oped countries (1). Despite improvements 
in surgical and adjuvant chemotherapy treat-
ment, mortality from CRC in Western coun-
tries remains high, with metastatic spread to 
the liver occurring in about 50% of patients 
(2). Although staging remains the most wide-
ly used prognostic indicator for CRC, increas-
ing evidence suggests that it is not sufficient 
for predicting the clinical outcome of these 
patients (2). This applies especially to patients 
with intermediate stage diseases (Duke’s B, 
T3-4N0M0), since clinical management for 
them has yet to be standardized (2). Clinical 
staging may be supplemented by the use of bi-
ological prognostic markers for invasion and 
metastasis. They may provide important infor-
mation needed for the implementation of vari-
ous novel therapeutic strategies for controlling 
disease progression and tumor cell dissemina-
tion (2).
Tumor cell invasion and metastasis are 
multi-step phenomena, involving the pro-
teolytic degradation of the basement mem-
brane and the extracellular matrix, altered 
cell adhesion, and physical movement of tu-
mor cells. It was shown that degradation of 
basement membrane and extracellular matrix 
play a crucial role in tumor invasion and me-
tastasis (3).
Tumor cells secrete proteolytic enzymes or 
induce host cells to secrete proteases. Extra-
cellular matrix degradation by proteases takes 
place not only in local invasion, but also in 
several stages of metastatic cascade, including 
angiogenesis, intravasation, and extravasation. 
The proteases involved in extracellular matrix 
degradation in tumor invasion and metasta-
sis are subdivided into four classes as follows: 
serine, cysteine, aspartic, and matrix metallo-
proteinases (MMPs). MMP-2 is responsible 
for degradation of collagen type IV, which is 
the major structural protein in the basement 
membrane. Therefore, activation of MMP-2 
is a crucial step in triggering the cascade of tu-
mor invasion and metastasis (4).
The prognostic significance of MMP-2 
overexpression in humans has been shown in 
breast cancer (5), head and neck tumors (6), 
and ovarian carcinomas (7).
The aim of this study was to determine the 
expression of MMP-2 using immunohisto-
chemical methods in a subpopulation of pa-
tients with Duke’s B colon cancer and exam-
ine its relationship with clinicopathological 
parameters and patient survival.
Patients and methods
Patients
This study included histological samples from 
152 patients diagnosed with Duke’s B colon 
cancer at the Department of Pathology, Split 
University Hospital, Split, Croatia, from Jan-
uary 1995 to December 1997.
Clinical data were collected from the De-
partment of Oncology, Split University Hos-
pital. Survival time of the patients was calcu-
lated as the interval from the date of diagnosis 
to the date of the last clinical control or death 
from the CRC-related causes until December 
31, 2006.
We determined conventional histopatho-
logical prognostic parameters of CRC, such as 
tumor grade, depth of invasion, and vascular 
invasion in hematoxylin-eosin sections of the 
specimens. Tumors were staged according the 
Duke’s staging system (8) and stratified into 
low and high grade tumors, as recommend-
ed by a multidisciplinary colorectal working 
group of a Consensus Conference, sponsored 
by the College of American Pathologists (9). 
According to this system, stratification is based 
solely on the proportion of gland formation by 
the tumor – low grade with <50% gland for-
mation and high grade with ≥50% gland for-
mation.
Croat Med J 2008;49:636-642
638
Immunohistochemical staining
We performed immunohistochemical staining 
on 5 μm-thick sections of the most representa-
tive paraffin blocks from each tumor.
Slides were dried overnight at 60°C and 
deparaffinized in xylene. Subsequently, they 
were rehydrated through graded alcohols into 
water. Heat-induced epitope retrieval was 
achieved by boiling sections in an EDTA buf-
fer, pH 8.9, in a microwave oven at 1000 W 
for 20 minutes (4 times per 5 minutes each). 
After boiling, sections were left to cool at 
room temperature for 20 minutes, rinsed thor-
oughly with water, and placed in TRIS-buff-
ered saline (TBS) for 5 minutes. Endogenous 
peroxidase was blocked with Peroxidase Block 
solution (provided in the EnVision kit, Daco-
Cytomation, Glostrup, Denmark) for 5 min-
utes, and slides were rinsed with TBS. Sections 
were incubated for 30 minutes with primary 
mouse monoclonal anti-human MMP-2 an-
tibody (clone MAB 902, dilution 1:30, R&D 
systems, Minneapolis, MN, USA).
Positive signal for MMP-2 was located in 
the cytoplasm of tumor cells and the stain-
ability was semiquantitatively estimated on 
the basis of percentage of positive stained tu-
mor cells. The stainability was scored as posi-
tive if ≥10% stained cells were found (7,10). 
We used slides of human placenta as posi-
tive control for MMP-2 immunohistochemi-
cal staining, as recommended by the manufac-
turer (R&D systems). The same sections were 
processed without primary antibodies as nega-
tive control.
Statistical analysis
χ2 test was used to examine the association be-
tween increased MMP-2 expression and vari-
ous clinicopathological characteristics. The 
Kaplan-Meier method was used to estimate 
survival as a function of time, and survival dif-
ferences were analyzed with log-rank test. Cox 
proportional hazard regression model was used 
to simultaneously examine all factors found to 
be prognostic of survival in univariate analy-
sis. Analyses were performed with Statistical 
Package for Social Sciences, version 9.0 (SPSS 
Inc., Chicago, IL, USA).
Results
The mean age of patients was 62 ± 8.8 years 
(range, 39-79). There were 57 (37.5%) women 
and 95 (62.5%) men.
During the follow-up period, 86 (56.6%) 
patients died – 72 (46.1%) from distant me-
tastasis and 14 (10.9%) from reasons unre-
lated to CRC. Median survival time was 60.5 
months (range, 5-117). There were 42 (28%) 
cases with high grade and 110 (72%) with low 
grade tumor. Vascular invasion was found in 
62 (41%) cases.
MMP-2 expression and correlation with other 
clinicopathological parameters
MMP-2 immunoreactivity presented as diffuse 
cytoplasmatic staining in tumor cells along the 
line of tumor invasion and in tumor cells with-
in lymphatic/blood vessels. We found some 
cytoplasmatic MMP-2 positivity in endothe-
lial cells, tumor associated macrophages, and 
fibroblasts of the stromal component. MMP-
Table 1. The association between overexpression of matrix me-
talloproteinase-2 (MMP-2) and clinicopathological variables in 
152 patients with Duke’s B colon cancer
No. (%) of patients with
MMP-2 expression†
Variable negative positive χ2 P
Sex: 4.8  0.028
 men 36 (38) 59 (62)
 women 32 (56) 25 (44)
Age (years): 0.335  0.930
  ≤60 32 (49) 33 (51)
 >60 36 (41) 51 (89)
Tumor differentiation:* 29.1 <0.001
 high grade  4 (10) 38 (90)
 low grade 64 (58) 46 (42)
Vascular invasion: 62.1 <0.001
 yes  4(6) 58 (94)
 no 64 (71) 26 (29)
*According to College of American Pathologists Consensus Statement 1999 (9).
†Staining intensity: negative –<10% cells with positive staining; positive –≥10% cells 
with positive staining (7,10).
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2 positive staining in ≥10% tumor cells was 
found in 84 (55%) cases.
A significant relationship was found be-
tween MMP-2 expression and other pathohis-
tological parameters characteristic of aggres-
sive behavior, such as high tumor grade and 
the presence of vascular invasion (Table 1). 
Univariate analysis confirmed that MMP-2 
expression, high tumor grade, presence of vas-
cular invasion, male sex, and age over 60 years 
were associated with the shorter overall surviv-
al (Table 2, Figures 1-4).
Cox multivariate analysis for overall surviv-
al showed that only vascular invasion and pos-
itive MMP-2 expression were connected with 
shorter overall survival (Table 2).
Discussion
Our results showed that immunohistochemi-
cally detected high expression of MMP-2 is a 
predictor of poor prognosis in patients with 
Duke’s B colon cancer.
The benefit of postoperative adjuvant che-
motherapy in patients with Duke’s B colon 
Figure 1. Overall survival and matrix metalloproteinase-2 (MMP-2) 
immunohistochemical expression in 152 patients with Duke’s B colon 
cancer. Full line – positive: ≥10% cells with positive staining; broken 
line – negative: <10% cells with positive staining. Statistical analysis 
was performed with Kaplan-Meier test.
Figure 2. Overall survival and tumor differentiation in 152 patients 
with Duke’s B colon cancer. Broken line – low grade tumor; full line 
– high grade tumor. Statistical analysis was performed with Kaplan-
Meier test.
Figure 3. Overall survival and vascular invasion in 152 patients with 
Duke’s B colon cancer. Broken line – tumor without invasion; full line 
– tumor with invasion. Statistical analysis was performed with Kaplan-
Meier test.
Figure 4. Overall survival and sex in 152 patients with Duke’s B colon 
cancer. Broken line – women; full line – men. Statistical analysis was 
performed with Kaplan-Meier test.
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cancer is still uncertain and its routine use is 
not recommended (11). Therefore, prognostic 
biomarkers may be useful for identifying high-
risk patients with resected, node-negative dis-
ease. Furthermore, indicators of biologic be-
havior in colon cancer may help supplement 
the staging system and provide a basis for the 
implementation of novel therapeutic strate-
gies targeting specific tumor-associated mole-
cules according to individual tumor biology.
Most studies on MMP-2 protein expres-
sion investigated colon and rectal cancer to-
gether (2,12-16), although their biological fea-
tures are heterogeneous (17,18), or only rectal 
cancer (10). Moreover, almost all studies in-
cluded patients in all clinical stages (2,12-16).
To our knowledge, this is the first study 
that used immunohistochemical methods to 
determine the expression of MMP-2 in the 
subpopulation of patients with Duke’s B co-
lon cancer and investigated its relationship 
with clinicopathological parameters and pa-
tient survival.
Previous studies on MMP-2 protein ex-
pression as a prognostic marker in colon carci-
noma used various methods, including gelatin 
zymography (19), enzyme linked immuno-
sorbent assays (19), quenched fluorescence 
substrate hydrolysis (20), Western blot (19), 
in situ hybridization (19), and immunohis-
tochemistry on formalin fixed, paraffin em-
bedded tissue (17,18). Immunohistochemis-
try has several advantages over other methods 
– it allows direct correlation with morpholo-
gy and it can be performed on paraffin embed-
ded specimens, which makes it practical for 
the routine assessment of MMPs in diagnos-
tic practice. However, it has been suggested 
that it cannot distinguish between latent and 
activated forms of MMPs (21). On the other 
hand, other techniques, such as zymography 
or quenched fluorescent substrate hydrolysis, 
are able to distinguish between the latent and 
active forms of MMP-s, but they do not allow 
a correlation with morphology (6,20).
We found the positive expression of MMP-
2 protein in 55% of samples, which is in line 
with other studies, where MMP-2 expression 
varied from 35% (10) to 68.8% (22).
MMP-2 immunoreactivity presented as a 
diffuse cytoplasmatic staining in tumor cells 
along the line of tumor invasion and in tumor 
cells within lymphatic/blood vessels, similar to 
other studies where increased levels of MMP-2 
protein were observed in the invasive region of 
colorectal tumors (23). This is in line with the 
hypothesis that MMP-2 provides a phenotyp-
ic hallmark of invasive potential and supports 
Table 2. Univariate and multivariate analysis of effect of matrix metalloproteinase-2 (MMP-2) overexpression, patients’ characteristics, 
and tumor parameters on overall survival in 152 patients with Duke’s B colon cancer*
Overall Univariate analysis (Kaplan-Meier test) Cox proportional hazard regression analysis
Parameter survival (SE) log rank P HR 95% CI P
Sex:  5.5  0.019 0.63 0.37-1.08  0.094
 women  77 (6)
 men  57 (5)
Age:  6.8  0.009 1.16 0.68-1.97  0.59
  ≤60  85 (5)
 >60  63 (4)
Tumor differentiation:† 20.1 <0.001 0.61 0.36-1.04  0.068
 low  77 (4)
 high  48 (4)
Vascular invasion: 72,0 <0.001 4.27 2.23-8.12 <0.001
 no  92 (4)
 yes  38 (3)
MMP-2:‡ 64.8 <0.001 3.64 1.79-7.36 <0.001
 negative 100 (4)
 positive  45 (4)
*Abbreviations: SE – standard error; HR – hazard ratio; CI – confidence interval.
†According to College of American Pathologists Consensus Statement 1999 (9).
‡Staining intensity: negative –<10% cells with positive staining; positive –≥10% cells with positive staining (7,10).
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the fact that the balance between proteases 
and antiproteases at the invading edge of the 
tumor is disrupted in favor of proteases (4).
We found some cytoplasmatic MMP-2 
positivity in endothelial cells, tumor associat-
ed macrophages, and fibroblasts of the stromal 
component, which confirms the earlier reports 
by Kikuchi (14) and Schwander (10).
Tumor cells interact with stromal cells in 
the metastatic cascade. After attachment to 
the components of the basement membrane, 
tumor cells secrete MMPs and other proteo-
lytic enzymes or induce host cells to produce 
proteases (4).
Positive immunostaining of MMP-2 signif-
icantly correlated with the presence of vascular 
invasion. These results are in concordance with 
other studies (14,15,24) and support the claim 
that MMP-2 has the key role in local expan-
sion and infiltration of the tumor cell mass, as 
well as metastatic invasion.
MMP-2, together with other MMPs, de-
grades collagen type IV and mobilizes vascular 
endothelial growth factor that is sequestered 
in the basement membrane. Degradation of 
collagen IV also exposes normally cryptic do-
mains of the protein, which serves as an im-
portant signal for angiogenesis. Finally, tumor 
gains access to the circulation by penetrating 
the vascular basement membrane (4).
Similar to studies by Ring (16) and Papan-
dopoulou (25), we found higher MMP-2 ex-
pression in high-grade tumors, although some 
studies show the opposite finding (13,19). 
Since tumor grade and vascular invasion are 
well-known prognostic factors (26), their cor-
relation with MMP-2 positive immunostain-
ing puts them in the group of pathohistolog-
ical parameters characteristic for aggressive 
tumor behavior.
Univariate analysis showed that MMP-
2 expression, high tumor grade, the presence 
of vascular invasion, male sex, and age over 
60 years were associated with shorter overall 
survival in patients with Duke’s B colon can-
cer. Other studies also showed that high tu-
mor grade and presence of vascular invasion 
were stage-independent prognostic factors in 
colorectal carcinomas (9,26,27).
Sex-related survival differences in patients 
with colorectal cancer were found in only two 
studies (28,29). Press et al (28) explained these 
differences by the fact the colon expresses 
both estrogen receptor β and androgen recep-
tor, and that epidermal growth factor receptor 
(EGFR), the high expression of which is linked 
with poor prognosis, interacts with both. They 
suggested that EGFR may have molecular in-
termediates that interact in a sex-specific way 
to affect EGFR pathway activation.
We found that both vascular invasion and 
MMP-2 were independent significant factors 
related to the overall survival. However, there 
are some limitations to our study, such as the 
relatively small number of respondents and 
the use of only immunohistochemical method 
for the detection of MMP-2 protein expres-
sion. Therefore, further studies on the impact 
of MMP-2 on the prognosis are needed. Such 
studies should include a homogenous and suf-
ficiently large patient-population, have a suffi-
ciently long follow-up period, and investigate 
colon and rectal cancer separately.
According to our results, the independent 
prognostic factor MMP-2 should be taken 
into consideration in decision making on the 
use of adjuvant systemic therapy in patients 
with Duke’s B colon cancer.
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